Search
Compass Therapeutics Inc.
CMPXAdd to Watchlist
0.857USD
-0.044-4.88%
Close 10-02 16:00（ET）
154.34MMarket Cap
LossP/E TTM
Pre-market 05:04 (ET)0.893USD+0.036+4.20%
Pre-market 05:04 (ET)Compass Therapeutics Inc. (CMPX) Stock Price Target & Forecast
Analyst Rating
Based on 15 analysts giving stock ratings to Compass Therapeutics Inc. in the past month.
Buy
7 Strong Buy
7 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
5.909USD+589.75%
CMPX Analyst Recommendation Trends
In the current month, CMPX has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CMPX average Analyst price target in the last month is 5.909.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
7
7
6
6
6
7
7
7
7
7
7
7
8
9
8
8
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15
15
14
14
15
16
15
15
CMPX Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, CMPX EPS is projected to reach -0.127 in FY2026Q3, following reported EPS of -0.135 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.09
-0.10
-0.11
-0.13
-0.14
Actual
-0.08
-0.10
-0.13
--
--
Surprise
+6.11%
-0.14%
-24.31%
--
--
FAQs
What is Compass Therapeutics Inc.'s price target?
Analysts forecast that Compass Therapeutics Inc.'s price target is USD 5.91, with the highest forecast at USD 12.00 and the lowest forecast at USD 1.00.
How have Compass Therapeutics Inc.CMPX's recent earnings per share performed?
The market expectation was USD -0.13, while Compass Therapeutics Inc.CMPX's earnings per share (EPS) for the previous quarter was USD -0.10. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for Compass Therapeutics Inc.?
Based on the ratings of Compass Therapeutics Inc.'s stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.